GSK to discontinue the manufacture and supply of Zantac products

News Image

MG News | May 19, 2020 at 11:31 AM GMT+05:00

0:00

May 18, 2020 (MLN): GlaxoSmithKline has decided to discontinue the manufacture and supply of the Ranitidine brand (Zantac).

Last year, the company was contacted by regulatory authorities regarding the detection of NDMA in Zantac (Ranitidine) products. Based on the information received and correspondence with regulatory authorities, GSK made the decision in September 2019 and extended it in October 2019, to initiate a voluntary pharmacy/retail level recall in all markets of Zantac products manufactured using all API sources, as a precautionary action.

The recall also applied to all Zantac products manufactured in Pakistan. GSK continued to respond to the queries received from the regulatory authorities and to work actively with them to address their concerns. It also conducted investigations into the potential source of the NDMA.

With the discontinuation of Zantac’s manufacture, the company has informed that there are alternatives medicines to Ranitidine available, as noted by the European Medicines Agency (EMA).

Copyright Mettis Link News

Related News

Name Price/Vol %Chg/NChg
KSE100 156,180.94
423.57M
0.51%
796.43
ALLSHR 95,690.82
1,354.89M
0.59%
557.25
KSE30 47,714.39
199.12M
0.52%
247.40
KMI30 229,722.09
134.66M
0.91%
2076.87
KMIALLSHR 64,420.07
581.33M
0.83%
532.01
BKTi 41,969.52
122.61M
0.50%
207.74
OGTi 31,991.76
10.82M
1.18%
372.62
Symbol Bid/Ask High/Low
Name Last High/Low Chg/%Chg
BITCOIN FUTURES 116,810.00 117,335.00
114,960.00
1235.00
1.07%
BRENT CRUDE 68.44 68.69
67.01
1.00
1.48%
RICHARDS BAY COAL MONTHLY 84.00 0.00
0.00
-0.40
-0.47%
ROTTERDAM COAL MONTHLY 93.35 93.50
93.15
0.50
0.54%
USD RBD PALM OLEIN 1,106.50 1,106.50
1,106.50
0.00
0.00%
CRUDE OIL - WTI 64.50 64.76
62.89
1.20
1.90%
SUGAR #11 WORLD 15.88 16.10
15.82
-0.12
-0.75%

Chart of the Day


Latest News

Top 5 things to watch in this week

Pakistan Stock Movers
Name Last Chg/%Chg
Name Last Chg/%Chg